Valeant Pharmaceuticals Intl Inc Has Another Very Negative Options Trading Session

 Valeant Pharmaceuticals Intl Inc Has Another Very Negative Options Trading Session

In today’s session Valeant Pharmaceuticals Intl Inc (VRX) recorded an unusually high (4,677) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious VRX decrease. With 4,677 contracts traded and 63594 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: VRX161118P00019000 closed last at: $2.2 or 57.1% up. About 8.99M shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 33.24% since April 5, 2016 and is downtrending. It has underperformed by 35.20% the S&P500.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 9 rate it a “Buy”, 2 “Sell”, while 12 “Hold”. This means 39% are positive. Valeant Pharmaceuticals Intl has been the topic of 75 analyst reports since July 21, 2015 according to StockzIntelligence Inc. JP Morgan maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, March 16 with “Overweight” rating. The rating was maintained by Deutsche Bank on Tuesday, October 20 with “Hold”. The firm has “Outperform” rating given on Tuesday, November 3 by RBC Capital Markets. Nomura downgraded it to “Neutral” rating and $60 target price in Wednesday, March 16 report. Rodman & Renshaw maintained it with “Buy” rating and $81 target price in Tuesday, August 9 report. RBC Capital Markets maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, October 12. RBC Capital Markets has “Sector Perform” rating and $35 price target. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Buy” rating given on Wednesday, June 8 by Stifel Nicolaus. JP Morgan maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, November 11 with “Overweight” rating. The rating was maintained by Morgan Stanley on Wednesday, March 16 with “Equal-Weight”. Stifel Nicolaus maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, March 16 with “Buy” rating.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

Insitutional Activity: The institutional sentiment decreased to 0.86 in Q2 2016. Its down 0.06, from 0.92 in 2016Q1. The ratio is negative, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.
Moreover, Highlander Capital Mgmt Llc has 0.22% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 12,000 shares. Moreover, Stanley Cap Mngmt Ltd Limited Liability Company has 1.17% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 57,800 shares. Ct Mason, a Massachusetts-based fund reported 12,517 shares. Synovus Corporation accumulated 1,750 shares or 0% of the stock. Archford Strategies Ltd holds 0% or 347 shares in its portfolio. Allianz Asset Mngmt Ag holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 129,586 shares. Ig Inv Limited last reported 0.03% of its portfolio in the stock. Winfield owns 75 shares or 0% of their US portfolio. George Kaiser Family Foundation accumulated 29,382 shares or 0.15% of the stock. Capital Fund Management holds 63,694 shares or 0.01% of its portfolio. Virginia Retirement Et Al has 60,600 shares for 0.02% of their US portfolio. Commonwealth Equity owns 22,143 shares or 0% of their US portfolio. Cibc Ww Markets, a Ontario – Canada-based fund reported 3.70M shares. Highland Cap L P has 57,500 shares for 0.05% of their US portfolio. Ruane Cunniff And Goldfarb accumulated 0.09% or 446,442 shares.

Insider Transactions: Since June 9, 2016, the stock had 2 insider buys, and 0 insider sales for $5.04 million net activity. $4.94 million worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was bought by PAPA JOSEPH C on Thursday, June 9. 4,000 shares with value of $98,600 were bought by KARABELAS ARGERIS N on Thursday, August 11.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $7.82 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Profitconfidential.com which released: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” on November 03, 2016, also Fool.com with their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016, Investorplace.com published: “Why Valeant Pharmaceuticals Intl Inc (VRX), Allergan plc Ordinary Shares (AGN …” on November 02, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Business.Financialpost.com and their article: “Can embattled Valeant Pharmaceuticals ‘drive the wolf from the door?'” published on November 07, 2016 as well as Investorplace.com‘s news article titled: “Make Valeant Pharmaceuticals Intl Inc (VRX) Stock Pay YOU” with publication date: October 28, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment